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BACKGROUND: The aim of this study is to seek an association between markers of metastatic potential, drug resistance-related protein
and monocarboxylate transporters in prostate cancer (CaP).
METHODS: We evaluated the expression of invasive markers (CD147, CD44v3-10), drug-resistance protein (MDR1) and
monocarboxylate transporters (MCT1 and MCT4) in CaP metastatic cell lines and CaP tissue microarrays (n¼140) by
immunostaining. The co-expression of CD147 and CD44v3-10 with that of MDR1, MCT1 and MCT4 in CaP cell lines was evaluated
using confocal microscopy. The relationship between the expression of CD147 and CD44v3-10 and the sensitivity (IC50)t o
docetaxel in CaP cell lines was assessed using MTT assay. The relationship between expression of CD44v3-10, MDR1 and MCT4 and
various clinicopathological CaP progression parameters was examined.
RESULTS: CD147 and CD44v3-10 were co-expressed with MDR1, MCT1 and MCT4 in primary and metastatic CaP cells. Both
CD147 and CD44v3-10 expression levels were inversely related to docetaxel sensitivity (IC50) in metastatic CaP cell lines.
Overexpression of CD44v3-10, MDR1 and MCT4 was found in most primary CaP tissues, and was significantly associated with
CaP progression.
CONCLUSIONS: Our results suggest that the overexpression of CD147, CD44v3-10, MDR1 and MCT4 is associated with CaP
progression. Expression of both CD147 and CD44v3-10 is correlated with drug resistance during CaP metastasis and could be
a useful potential therapeutic target in advanced disease.
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Prostate cancer (CaP) remains the most common cancer and the
second leading cause of death from cancer in males in the United
States (Jemal et al, 2009). Although early-stage CaP can be
controlled using conventional therapies, multidrug resistance
(MDR) and tumour metastasis remain the main causes of
treatment failure and mortality in CaP patients. The majority of
deaths in CaP result from progression to androgen-independent
disease (Valdespino et al, 2007). For androgen-independent CaP,
chemotherapy is the standard treatment option for palliation of
symptoms associated with the disease. However, the drug-resistant
nature of CaP minimises therapeutic efficacy, and consequently,
most patients die within 12 months. The relationship between
tumour metastasis and MDR is not fully defined in CaP, although
indirect evidence in advanced disease suggests a functional link
between these processes
CD147 (EMMPRIN, extracellular matrix metalloproteinase
inducer protein) is a multifunctional glycoprotein that can modify
the tumour microenvironment by activating proteinases, inducing
angiogenic factors in both tumour and stromal cells, and
regulating growth and survival of anchorage-independent tumour
cells (micrometastases) and MDR expression (Yan et al, 2005).
CD147 is highly expressed on the surface of various tumours,
including CaP, and is associated with cancer progression
(Riethdorf et al, 2006). Transcriptome analysis and comparative
genomic hybridisation of individual tumour cells isolated from
the bone marrow of patients with CaP have shown that CD147 is
the most frequently expressed protein in primary tumours
and micrometastases (Klein et al, 2002). Moreover, CD147
expression is considered a significant prognostic factor in human
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sCaP (Zhong et al, 2008). Our recent results show that high-level
CD147 expression is significantly correlated with CaP progression
to high-grade disease, and is associated with the expression of
MMPs in both tumour and stromal cells, including fibroblasts and
endothelial cells (Madigan et al, 2008).
CD44 is a multifunctional protein involved in cell adhesion,
migration and drug resistance. Alternative splicing of the
CD44 gene produces many CD44 isoforms or variants (CD44v),
some of which form the invariant extracellular domain of
standard CD44 (CD44s). CD44s is expressed in the majority of
normal basal prostate cells; however, CD44v expression is reported
in CaP (Harrison et al, 2006). The role of CD44 in CaP
development and progression is controversial, with studies
showing both tumour-promoting and tumour-inhibiting effects
(Gao et al, 1998; Omara-Opyene et al, 2004). Clearly the
involvement of CD44 and its variants in CaP progression and
metastasis is complex.
A major mechanism for drug resistance in cancer is through
energy-dependent efflux pumps that reduce intracellular drug
accumulation. One of these, which is well characterised, is MDR1/
P-glycoprotein (P-gp) or ABCB1, a 170-kDa membrane phospho-
glycoprotein encoded by the mdr1 gene (MDR1) (Germann, 1996).
Previous studies indicated that CD147 expression is upregulated in
MDR cancer cells, and also demonstrated that CD147 increases
the activity of MMPs in MDR-expressing breast cancer cell lines
(Yang et al, 2003). Treatment of MDR-expressing breast cancers
with P-gp substrates can adversely affect therapeutic outcomes
through modulation of CD147, MMP-2, MMP-9 and EGFR
production (Li et al, 2007). Hyaluronan (HA) production in
mammary carcinoma cells is also increased by CD147, with MDR
being induced in an HA-dependent manner (Marieb et al, 2004).
Expression of CD44 and MDR1/P-gp seems to be co-regulated, as
modulation of CD44 expression correspondingly affects MDR1/
P-gp expression in breast cancer (Miletti-Gonza ´lez et al., 2005).
Previous studies indicate that both CD44 and HA are involved in
chemotherapeutic drug resistance in many cancer types (Misra
et al, 2005; Ohashi et al, 2007), but regulation of MDR by CD147
and CD44 in CaP remains to be fully defined.
Tumour cell invasion and development of MDR are associated
with hypoxia and low tumour pH. Several studies show a direct
relationship between increased cancer cell glucose uptake,
glycolysis and tumour aggressiveness. Non-invasive spectroscopy
imaging for hyperpolarised lactate also shows elevated lactate for
high-grade CaP in a transgenic mouse model, compared with
normal prostate (Albers et al, 2008). Tumour cell expression of
MCT1 and MCT4 has been reported to be regulated by CD147
(Kirk et al, 2000). Specifically, interaction of CD147 with MCT1
or MCT4 within the endoplasmic reticulum is necessary for
MCT trafficking to the plasma membrane; without CD147, MCTs
are degraded and thus non-functional (Gallagher et al, 2007).
However, the relationship of MCTs with CD147, CD44 and MDR1
in CaP is still unclear.
In this study, we investigated whether there is an association
between markers of metastatic potential (CD147, CD44v3-10),
MDR-related protein (MDR1) and monocarboxylate transporters
(MCT1 and MCT4), and CaP progression and chemoresistance.
We found colocalisation of CD147, CD44v3-10, MDR1, MCT1
and MCT4 in metastatic CaP cells lines; Expression of CD147
and CD44v3-10 in metastatic CaP cells was inversely related to
docetaxel sensitivity (IC50). In addition, we confirmed the
colocalisation of CD147 and CD44v3-10 with MDR1, MCT1 and
MCT4 in low- and high-grade primary CaP tissues, and demon-
strated that overexpression of CD44v3-10, MDR1 and MCT4 is
related to clincopathological markers of CaP progression. Our
results suggest that CD147 and CD44v3-10 are associated with CaP
drug resistance and metastasis, and could be useful therapeutic
targets to prevent the development of incurable, recurrent and
drug-resistant CaP.
MATERIALS AND METHODS
Antibodies
The following antibodies and conjugates were used: mouse anti-
EMMPRIN/CD147 monoclonal antibody (MAb) (8D6), rabbit
polyclonal anti-human MDR1 antibody (sc-1517-R), rabbit poly-
colonal anti-MCT1 antibody (H-70), rabbit polycolonal anti-MCT4
(H-90) (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA); goat
polyclonal anti-CD44v3-10 antibody (Alexis Biochemicals, San
Diego, CA, USA); Alexa Fluor-488 goat anti-mouse IgG, Alexa
Fluor-488 donkey anti-goat IgG, AlexaFluor-594 goat anti-rabbit
IgG, Alexa Fluor-594 donkey anti-goat IgG (Molecular Probes,
Eugene, OR, USA); biotinylated swine anti-goat, mouse, rabbit
immunoglobulins (Igs), streptavidin/HRP, mouse anti-human IgG1
negative control antibodies (Dako, Glostrup, Denmark); mouse
anti-human MDR1 MAb (F4) mouse anti-b-tubulin MAb and goat
or rabbit Ig (Sigma-Aldrich Pty Ltd, Castle Hills, NSW, Australia).
Cell lines and cell culture
Androgen-non-responsive (PC-3-RX-DT2R, PC-3, DU145) and
androgen-responsive (LNCaP-LN3, DuCaP) CaP cell lines from
different sources were studied (Supplementary Table 1s). Tissue
culture reagents were supplemented with 10% (v/v) heat-inacti-
vated fetal bovine serum (Invitrogen Australia Pty Ltd, Melbourne,
VIC, Australia), unless otherwise stated. PC-3-RX-DT2R, PC-3 and
DU145 cells were cultured in RPMI-1640; LNCaP-LN3 cells in
1:1 RPMI-1640:F12-K; and DuCaP cells in DMEM. All were grown
in a humidified incubator at 371C with 5% CO2. After 48h culture,
sub-confluent cells were rinsed twice with Dulbecco’s phosphate-
buffered saline (PBS) (pH 7.2), detached with 0.25% trypsin/0.05%
EDTA in PBS at 371C, collected by centrifugation and resuspended
in buffer (see below).
The PC-3-RX-DT2R cell line was developed by Russell’s group,
by exposing xenografts of PC-3 to three doses of docetaxel
at 12.5mgkg
–1 at 5-day intervals, intravenously, allowing the
tumours to regress and then retreating the mice after their regrowth.
Tumours that regrew after the second round of treatment were used
to establish a line in culture. The cells were cultured in vitro with
continuous exposure for 7 days to docetaxel at 1–1.25 10
 9 M,
followed by a 14-day recovery period in the absence of added
docetaxel through three rounds of treatment to establish them as
a drug-resistant cell line, PC-3-RX-DT2R. DuCaP cells were provided
by Dr K Pienta (University of Michigan Comprehensive Cancer
Center, Ann Arbor, MI, USA). PC-3 and DU145 CaP cell lines were
obtained from American Type Culture Collection (ATCC, Rockville,
MD, USA). LNCaP-LN3 cells were kindly provided by Dr C Pettaway
(M. D. Anderson Hospital, Austin, TX, USA).
Immunofluorescence confocal microscopy analysis of
CaP cell lines
To determine the cellular localisation of CD147, CD44v3-10,
MDR1, MCT1 and MCT4 in CaP cells, PC-3-RX-DT2R, PC-3,
DU145, LNCaP-LN3 and DuCaP cells were grown on glass
coverslips (10
5 cells) for 24h. After washing with Tris-buffered
saline (TBS) (pH 7.5), cells were fixed on coverslips in ice-cold
methanol for 10min at room temperature (RT) and then incubated
with 10% normal goat serum in TBS for 20min to suppress non-
specific binding of IgG. After rinsing in TBS, the cells were
incubated in mouse anti-CD147 (1:400 dilution), goat anti-
CD44v3-10 (1:400 dilution), rabbit anti-MDR1 (1:400 dilution),
MCT1 (1:400 dilution) and rabbit anti-MCT4 (1:400 dilution)
antibodies for 1h at RT on a shaking table and rinsed with TBS,
followed by a 45-min incubation in Alexa Fluor-488 goat anti-
mouse, donkey anti-goat or Alexa Fluor-594 goat anti-rabbit IgG
(1:1000 dilution) at RT. The stained cells were mounted with
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sglass slides using glycerol (Sigma-Aldrich Pty Ltd.). Slides were
examined using an FV300/FV500 Olympus laser scanning confocal
microscope (Olympus, Tokyo, Japan). Negative control slides
were treated identically but with either isotype control MAbs or
by omitting primary antibodies. We used a constant setting
for laser power and detector gain for confocal microscopy.
Multichannel excitation was minimised using fluorochromes
with peak excitation of 488 and 594nm, respectively. Emission
bleed-through was minimised using multitrack methods in which
sequential image capture with a single detection channel was
performed and images then combined. This corrects for the effects
of emission crosstalk.
Western blot analysis
Protein expression levels were determined by western blot analysis.
Briefly, cells were lysed in a buffer containing 50mmoll
–1
Tris–HCl (pH 8.0), 150mmoll
–1 sodium chloride (NaCl), 0.1%
SDS, 10mmoll
–1 sodium fluoride (NaF), 1mmoll
–1 sodium
orthovanadate (Na3VO4), 0.5% sodium deoxycholate, 1% Triton
X-100 and 1/12 (v/v) protease inhibitor cocktail. The lysates
were centrifuged at 13000r.p.m. for 10min at 41C and the
supernatants were collected for determining protein concentration
using a BCA protein assay reagent (Thermo Scientific, Waltham,
MA, USA). Equal amounts of total protein were separated by
NuPAGE 4–12% Bis–Tris gel (Invitrogen Australia Pty Ltd)
electrophoresis at 200V for 50min and then transferred to a PVDF
membrane in NuPAGE transfer buffer at 30V for 1.5h. Membranes
were blocked with either 5% bovine serum albumin (Sigma-
Aldrich Pty Ltd) or 5% skim milk in PBS/0.05% Tween 20 buffer.
Blots were incubated overnight with specific antibodies at
appropriate concentrations (CD147 1:300, CD44v3-10 1:100,
mouse anti-MDR1 (F4) 1:500, MCT1 1:200 and MCT4 1:300
dilution) at 41C. After washing for 3 10min in PBS/0.05% Tween
20 buffer, blots were then incubated for another 1h with an HRP-
conjugated IgG secondary antibody (Santa Cruz Biotechnology
Inc, 1:5000 dilution). After washing for 3 10min in PBS/0.05%
Tween 20 buffer, immunoreactive bands were detected using ECL
western blotting substrate (SuperSignal West pico Substrate,
Thermo Scientific), followed by exposure to film and photographic
development. To confirm equal loading of protein lysates,
membranes were stripped (Restore Western Blot Stripping Buffer,
Thermo Scientific) and re-probed using mouse anti-b-tubulin
MAb (1:10000 dilution), then processed as above. Films were
scanned and processed in Adobe Photoshop.
MTT assay
PC-3-RX-DT2R, PC-3, DU 145, LNCaP-LN3 and DuCaP cells were
seeded in triplicate in 96-well plates at 5000 cells per well and
incubated for 24h. A range of concentrations of docetaxel (Sigma-
Aldrich, St Louis, MO, USA) diluted in 100% ethanol (1000, 100,
10, 1, 0.1, 0.01, 0.001, 0.0001nM) was added to the cells. Control
cells were treated with appropriate volumes of 100% ethanol. After
48h, 20ml of MTT (5mgml
–1) (Sigma-Aldrich Pty Ltd.) was added
to each well, followed by incubation at 371C/5% CO2 for 4h.
Subsequently, 100mL of DMSO (Sigma-Aldrich Pty Ltd.) was added
and the plate was shaken for 20min at RT to dissolve the formazan
crystals. The absorbance (OD) was read at a wavelength of 562nm
on a BIO-TEK microplate reader (Bio-Rad, Hercules, CA, USA).
Each experiment was repeated at least three times. Results
represent the OD ratio of treated and untreated cells. The growth
inhibition curve was generated using the GraphPad Prism 4
Program (GraphPad, San Diego, CA, USA). Absolute IC50 values
were calculated using the intersection of the 50% normalised drug
response and the growth inhibition curves for each cell line, to find
the x axis values for IC50 docetaxel concentration (nM) (also
log10(nM)).
Patients and clinical data
As described previously (Cozzi et al, 2006), 140 CaP tissues were
obtained with informed consent from patients with localised CaP
undergoing radical resection of the prostate (RRP) or transurethral
resection of the prostate at Urology Sydney, St George Private
Hospital, from 2000 to 2007. Controls (n¼40) were from normal
biopsy samples or from morphologically normal areas of CaP
tissue. Ethical approval was obtained from the South East
Area Health Human Research Ethics Committee, South Section.
Specimens were grouped as follows: Group I: normal prostate
glands (age o40 years, range 26–38 years, n¼10; age 450 years,
range¼55–83 years, n¼10), normal areas of prostate glands
from CaP patients (median age 67 years, range 62–84 years,
n¼20), benign prostate hyperplasia (BPH) (median age 66 years,
range 58–72 years, n¼40), prostatic intraepithelial neo-
plasia (PIN) (median age 63 years, range 57–71 years, n¼20);
Group II: 120 CaP specimens (96 RRP, 24 transurethral resection of
the prostate), containing Gleason score o7( n¼30), Gleason
score¼7( 3 þ4) (n¼30), Gleason score¼7( 4 þ3) (n¼30),
Gleason score 47( n¼30), with median age 61 years (range
46–76 years).
Formalin-fixed tissues were routinely processed, paraffin-
embedded and H&E sections were reviewed. Tumour foci were
identified, circled in ink and graded (Gleason system). Pathological
stage (RRP) was determined using the TNM system. Clinical
data in RRP patients (n¼96) indicated an average age at surgery
of 63 years (range 49–72 years) and median follow-up time
of 18 months (range 2–50 months). A detectable level of PSA
(40.2ngml
–1) after surgery was defined as biochemical recur-
rence (Cozzi et al, 2006). Pertinent clinical information (pretreat-
ment PSA level, Gleason score, clinical stage, surgical margin
status, assessment by clinic visit, phone or e-mail contact to
determine overall, cancer-specific and recurrence-free survival)
was recorded. All patients were advised to undergo a serum PSA
test twice a year.
TMAs
Tissue microarrays (TMAs) were constructed (Cozzi et al, 2006)
with three tissue cores (diameter 1.0mm)/donor block within
the marked areas, being arrayed into a recipient paraffin
block (35mm 20mm) of semiautomated Beecher Instruments
(Silver Springs, MD, USA). Sections (5mm) were cut, collected
on Superfrost Plus slides (Lomb Scientific, Sydney, NSW,
Australia) and H&E staining was performed.
Immunohistochemistry
To examine for expression of CD44v3-10, MDR1, MCT1 and MCT4
immunoreactivity, paraffin-embedded TMAs were deparaffinised
in xylene, followed by a graded series of ethanol (100, 95, 75 and
50%) and re-hydration in TBS. Slides were immersed in 0.01 M
citrate buffer (pH 6.0) for 20min at 1001C to enhance antigen
retrieval, rinsed in TBS and then treated with 3% hydrogen
peroxide, and again rinsed in TBS. After blocking in 10% normal
swine serum in TBS for 30min, sections were incubated overnight
at 41C in goat anti-CD44v3-10 (1:200 dilution), rabbit anti-MDR1
(1:200 dilution), rabbit anti-MCT1 (1:200 dilution) and rabbit
anti-MCT4 (1:200 dilution) Polyclonal antibodies (PAbs),
washed in TBS, then incubated in biotinylated swine anti-goat
or rabbit Ig (1:150) for 45min at RT, rinsed in TBS and
then incubated in streptavidin/HRP (1:200) for 30min at RT.
After rinsing in TBS, immunoreactivity was developed with
3,30 diaminobenzidine substrate and counterstained with haema-
toxylin. Negative controls were treated identically but incubated in
control PAbs (nonspecific goat or rabbit Ig), or the primary
antibody was omitted.
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To examine the colocalisation of CD147, CD44v3-10, MDR, MCT1
and MCT4 in CaP tissues, whole sections (10 CaP specimens from
each subgroup based on TMA immunohistochemistry results,
n¼40) were incubated overnight at 41C in primary mouse anti-
CD147 (1:200 dilution) MAb, or in goat anti-CD44v3-10 (1:200
dilution), rabbit anti-MDR1 (1:300 dilution), rabbit anti-MCT1
(1:200 dilution) and rabbit anti-MCT4 (1:200 dilution) PAbs.
After washing with TBS, sections were incubated in goat anti-
mouse Alexa 488 (CD147), goat anti-rabbit Alexa 594 (MDR1,
MCT1 and MCT4) and donkey anti-goat Alexa 488 or 594 (for
goat CD44v3-10) for 1h at RT, and rinsed in TBS. Controls were
treated identically, using nonspecific Igs (goat or rabbit Ig) as
negative controls. Sections were examined using an FV 300/FV500
Olympus laser scanning confocal microscope (Olympus). We used
a constant setting for laser power and detector gain for confocal
microscopy, and multitracking and sequential image capture was
used to correct signal emission crosstalk between neighbouring
channels, and the images were combined.
Assessment of immunostaining results
Immunostaining results were assessed by staining intensity
(Grade 0–3) for cancer cell lines, TMA tissue and whole primary
prostate and CaP tissues using light microscopy (Leica micro-
scope, Nussloch, Germany) and confocal microscopy. The criteria
for assessment were as follows: 0, negative); 1, weak); 2, moderate);
3, strong). For TMA staining, three cores were scored per case. The
analysis of three cores per case has been shown to be comparable
with the analysis of the whole section in a previous study (Rubin
et al, 2002). In instances in which all three cores from one tumour
were positive (3 of 3), the reading was counted as positive. In
situations in which heterogeneous staining was seen among the
three cores, an average score was determined. Evaluation of tissue
staining was performed independently by three experienced
observers (JLH, HMC and YL). All specimens were scored blind
and an average of grades was taken. If discordant results were
obtained, differences were resolved by joint review and consulta-
tion with a third observer (WD) experienced in immunopathology.
For statistical analysis, CaP patients from RRP cases were divided
into two groups: the low-expression group, comprising Grade
0 and 1 immunostaining, and the high-expression (overexpression)
group, comprising Grade 2 and 3 immunostaining.
Statistical analysis
The associations between CD44v3-10, MDR1 and MCT4 expression
levels (low-expression and high-expression groups) and clinico-
pathological data were tested using a w
2-test. Comparison of
staining intensity for CD44v3-10, MDR1, MCT1 and MCT4
between CaP tissues and normal prostate tissues was performed
using the w
2-test, where Po0.05 (two tailed) was considered
significant. All statistical analyses were performed using GraphPad
Prism 4.00 (GraphPad).
RESULTS
Expression and colocalisation of CD147, CD44v3-10,
MDR1, MCT1 and MCT4 in metastatic and
drug-resistance CaP cell lines
Immunofluorescence labelling of CaP cells with CD147, CD44v3-10,
MDR1, MCT1 and MCT4 antibodies showed positive staining
in PC-3-RX-DT2R, PC-3, DU145 and LNCaP-LN3 CaP cells, with
variation between cell lines (Figure 1). Strong (Grade 3) expression
of CD147, CD44v3-10, MDR1, MCT1 and MCT4 expression was
found in PC-3-RX-DT2R and PC-3 cell lines. Medium expression
of CD147, CD44v3-10, MDR1 and MCT1 and strong expression of
MCT4 were found in DU145 cells. Low expression of CD147,
CD44v3-10, MDR1 and MCT1 and medium expression of MCT4
were found in the LNCaP-LN3 cell line. DuCaP cells showed no
staining for CD147 and CD44v3-10, and weak immunostaining for
MDR1, MCT1 and MCT4. The immunostaining grades are
summarised in Supplementary Table 2s. Membrane expression
was found for CD44v3-10 PAb, whereas expression of both
membrane and cytoplasm was seen for CD147, MDR1, MCT1
and MCT4 antibodies. Strong colocalisation of CD147/CD44v3-10,
CD147/MDR1, CD147/MCT1, CD147/MCT4, CD44v3-10/MDR1,
CD44v3-10/MCT1 and CD44v3-10/MCT4 was observed in PC-3-
RX-DT2R, PC-3 and DU 145 non-androgen-responsive metastatic
CaP cell lines; weak colocalisation of these markers was observed
in the LNCaP-LN3 cell line but no colocalisation was found in the
DuCaP androgen-responsive CaP cell line (Figure 1 and Supple-
mentary Figure 1s). The immunofluorescence results for the
expression of CD147, CD44v3-10, MDR1, MCT1 and MCT4 in CaP
cell lines were further confirmed by western blotting and high
levels of these proteins were found in PC-3-RX-DT2R and PC-3 cell
lines (Figure 2).
Expression of CD147 and CD44v-3-10 is related with
docetaxel response in metastatic CaP cell lines
Metastatic CaP cell lines (PC-3-RX-DT2R, PC-3, DU145, LNCaP-
LN3 and DuCaP) with different levels of CD147 and CD44v3-10
expression responded differently to docetaxel treatment. The IC50
values for these CaP cell lines were highly related to the levels of
CD147 and CD44v3-10 expression (see Figure 3 and Supplemen-
tary Table 2s). Thus, PC-3-RX-DT2R drug-resistant cells (CD147
and CD44v3-10, Grade3) were the least sensitive (IC50: 44.7nM),
whereas DuCaP cells (CD147 and CD44v3-10, Grade 0) were very
sensitive to docetaxel treatment (IC50:4n M).
Expression of CD44v3-10, MDR1, MCT1 and MCT4
in CaP tissues
We previously reported CD147 expression in these TMAs
(Madigan et al, 2008). In this study, we immunostained for
CD44v3-10, MDR1, MCT1 and MCT4. In primary CaP tissues, 74
(89 of 120), 78 (94 of 120), 88 (106 of 120) and 92% (110 of
120) were positive for CD44v3-10, MDR1, MCT1 and MCT4 (Grade
1–3), respectively. In CD44v3-10-positive primary CaP sections,
weak staining (Grade 1) was found in 16% (14 of 89) (Figure 4A),
moderate staining (Grade 2) in 45% (40 of 89) (Figure 4B) and
strong staining (Grade 3) in 39% (35 of 89) (Figure 4C), whereas no
staining was observed in negative controls (Figure 4D).
In MDR1-positive primary CaP sections, weak staining
(Grade 1) was found in 17% (16 of 94) (Figure 4E), moderate
staining (Grade 2) in 44% (41 of 94) (Figure 4F) and strong
staining (Grade 3) in 39% (37 of 94) (Figure 4G), whereas no
staining was found in negative controls (Figure 4H).
The immunostaining patterns and percentage of positive cells
for MCT1 and MCT4 in TMAs were similar, and MCT4 results are
presented as representative of this study. In MCT4-positive
primary CaP sections, weak staining (Grade 1) was found in 20%
(22 of 110) (Figure 4I), moderate staining (Grade 2) in 38% (42 of
110) (Figure 4J) and strong staining (Grade 3) in 42% (46 of 110)
(Figure 4K), whereas no staining was found in negative controls
(Figure 4L).
No CD44v-3-10, MDR1, MCT1 and MCT4 immunostaining was
found in normal prostate tissues and PIN and in non-tumour
regions from primary CaP tissues (data not shown). Scattered
areas of weak (pGrade 1) heterogeneous epithelial cell staining
were observed in 3% (1 of 40) for MDR1, and in 5%
(2 of 40) for MCT4 in BPH specimens (Supplementary Table 3s).
The staining intensity and percentage of positive staining for
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CD147/MDR1
CD147/MCT1
CD147/MCT4
Figure 1 Co-immunolabelling of CD147, CD44v3-10, MDR1, MCT1 and MCT4 in metastatic prostate cancer (CaP) cell lines. Representative confocal
images of CD147 (green), CD44v3-10, MDR1, MCT1 and MCT4 (red) expression are shown. Merged images and red and green channels are shown
separately. Membrane expression was found for CD147 and CD44v3-10 antibodies, whereas expressions of both membrane and cytoplasm were seen for
MDR1, MCT1 and MCT4 antibodies. All immunostainings are more homogeneous. (A) CD147; (B) CD44v3-10; (C) MDR1; (D) MCT1; (E) MCT4; (F)
colocalisation of CD147 with CD44v3-10; (G) colocalisation of CD147 with MDR1; (H) colocalisation of CD147 with MCT1; (I) colocalisation of CD147
with MCT1. Magnification: A–I  400. The colour reproduction of the figure is available on the html full text version of the paper.
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BPH and normal prostates are summarised in Supplementary
Table 3s and Supplementary Table 4s. For CaP specimens, the
immunostaining was mostly Grade 2 or 3, but was negative in
PIN specimens.
Expression of CD44v3-10, MDR1, MCT1 and MCT4 was gene-
rally uniform in most tumours. The expression of CD44v3-10
was mostly cell membrane associated; however, distinct positive
cytoplasmic staining was also seen. Immunostaining for MDR1,
MCT1 and MCT4, as well as some membrane staining, was mainly
cytoplasmic. In high-grade primary CaP (Gleason score X7), the
tumour stroma generally showed a strong positive reaction for
CD44v3-10, MDR1, MCT1 and MCT4 (data not shown).
Correlation between CD44v3-7, MDR1 and MCT4
expression and clinicopathological parameters
Of the 96 RRP patients, only 9% (9 of 96) relapsed with biochemical
progression (PSA40.4), and no patients died of CaP during the
follow-up period (5 years). The median time to relapse was 40
months (range 18–50 months). In all, 26% (25 of 96) of tumours
had a Gleason score o7 whereas 74% (71 of 96) of tumours had a
Gleason score X7. In all, 27% (26 of 96) of tumours were small
(pT1), 38% (36 of 96) were organ confined (stage pT2) and 36%
(34 of 96) had extracapsular extension (stage pT3). Table 1
summarises the correlations between CD44v3-10, MDR1 and
MCT4 expression in primary CaP with a pretreatment PSA level,
Gleason score, pathological stage, surgical margin status, nodal
involvement (development of metastases) and biochemical recur-
rence. Overexpression (high-expression group) of CD44v3-10,
MDR1 and MCT4 was significantly correlated with pretreatment
PSA levels (Po0.05), and increased with progression of CaP
(Gleason score, Po0.05; pathological stage, Po0.05; nodal involve-
ment, Po0.05). Overexpression of CD44v3-10 and MDR1, but not of
MCT4, was also significantly correlated with PSA-defined recurrence
(Po0.05). There was no correlation between overexpression of
CD44v3-10, MDR1 or MCT4 and surgical margin (P40.05).
Co-immunolabelling of primary CaP tissues with CD147,
CD44, MDR1, MCT1 and MCT4 antibodies
Colocalisation of CD147 and CD44v3-10, MDR1, MCT1and MCT4
was also assessed in primary CaP tissues (n¼40) by confocal
microscopy. Most samples displayed co-immunolabelling with two
different markers, although immunostaining for single antibody in
different samples was variable. The immunostaining patterns are
very similar to those seen by peroxidase immunohistochemistry as
described above. Representative images from different tumours
are shown in Figure 5. For co-immunolabelling of CD147 with
CD44v3-10 (Figure 5A), CD147 with MDR1 (Figure 5B), CD147
with MCT1 (Figure 5C), CD147 with MCT4 (Figure 5D), CD147 is
green, whereas CD44v3-10, MDR1, MCT1 and MCT4 expression
is red. For co-immunolabelling of CD44v3-10 with MDR1
(Figure 5E), MCT1 (Figure 5F) and MCT4 (Figure 5G), CD44v3-10
is green, whereas MDR1, MCT1 and MCT4 expression is red.
DISCUSSION
In this study, we examined the expression of CD147, CD44v3-10,
MDR1, MCT1 and MCT4 in metastatic CaP cell lines, in primary
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DuCaP
CD147 (35-55kDa) 
MCT4 (54kDa)
CD44v3-v10
(200–250kDa)
MDR1 (170kDa)
β-tubulin (55kDa)
MCT1 (50kDa)
Figure 2 Expression of CD147, CD44v3-10, MDR1, MCT1 and MCT4
in prostate cancer (CaP) cell lines by western blotting. A representative
western blot showing high levels of CD147, CD44v3-10, MDR1 (F4),
MCT1 and MCT4 expression in PC-3-RX-DT2R and PC-3 cell lines,
moderate expression in DU 145 cells and low or no expression in LNCaP
and DuCaP cells. Equal loading is demonstrated with b-tubulin antibody in
the bottom panel (lane 1: RX-DT2R, lane 2: PC-3, lane 3: DU145, lane 4:
LNCaP-LN3. lane 5: DuCaP).
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Figure 3 Dose response of metastatic prostate cancer (CaP) cell lines to docetaxel measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay. Drug-resistant and metastatic CaP cell lines treated with a range of concentrations of docetaxel (0.001–1000nM, x axis) showed
varying responses. The IC50 value (50% normalised cell response) is related to the expression of CD147 and CD44v3-10. For example, the drug-resistant
cell line, PC3-RX-DT2R, displays Grade 3 CD147 and CD44v3-10 expression, and an IC50 of 44.7nM (x axis); the drug-sensitive CaP cell line, DuCaP,
displays Grade 0 CD147 and CD44v3-10 immunostaining and the lowest IC50 of 4nM (x axis) (n¼3, mean±s.d.).
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and investigated further possible associations among these
markers. High levels of CD147, CD44v3-10, MDR1, MCT1 and
MCT4 were observed in metastatic and drug-resistant CaP cell
lines and in specimens of advanced CaP, but not in PIN, BPH and
normal prostate tissues. Colocalisation of invasive and metastatic
Weak
CD44v3-10
MDR1
MCT4
Control Strong Medium
Figure 4 Expression of CD44v3-10, MDR1 and MCT4 in prostate cancer (CaP) tissue microarrays (TMAs). Representative images are shown of Grade 1
(weak) CD44v3-10 (A), MDR1 (E) and MCT4 (I); Grade 2 (medium) CD44v3-10 (B), MDR1(F) and MCT4 (J); and Grade 3 (strong) CD44v3-10 (C),
MDR1(G) and MCT4 (K) immunostaining. No immunoreactivity is seen in non-specific negative controls for CD44v3-10 (D), MDR1 (H) and MCT4 (L).
Brown colour indicates positive immunostaining. Insets indicate the typical areas of staining at high amplification. Magnification: A–L  10; and insets  40.
The colour reproduction of the figure is available on the html full text version of the paper.
Table 1 Clinicopathological characteristics associated with CD44v3-10, MDR1 and MCT4 expression in primary CaPs (RRP patients, n¼96)
CD44v3-10, MDR1 and MCT4 expression/total number (%)
CD44v3-10 MDR1 MCT4
Variable LEG
a HEG
b P-value
c LEG HEG P-value
c LEG HEG P-value
c
Pretreatment PSA level (ngml
–1)
o10 53% (21/40) 47% (19/40) 0.001 45% (18/40) 55% (22/40) 0.014 35% (14/40) 65% (26/40) 0.004
X10 21% (12/56) 79% (44/56) 21% (12/56) 79% (44/56) 11% (6/56) 89% (50/56)
Gleason score
o7 52% (13/25) 48% (12/25) 0.031 56% (14/25) 44% (11/25) 0.002 36% (9/25) 64% (16/25) 0.029
X7 28% (20/71) 72% (51/71) 23% (16/71) 77% (55/71) 15% (11/71) 85% (60/71)
Pathological stage
pT1 54% (14/26) 46% (12/26) 0.041 58% (15/26) 42% (11/26) 0.002 42% (11/26) 58% (15/26) 0.006
pT2 30% (11/36) 70% (25/36) 25% (9/36) 75% (27/36) 11% (4/36) 89% (32/36)
pT3 24% (8/34) 76% (26/34) 18% (6/34) 82% (28/34) 15% (5/34) 85% (29/34)
Nodal involvement
No 40% (32/81) 60% (49/81) 0.014 36% (29/81) 64% (52/81) 0.024 25% (20/81) 75% (61/81) 0.031
Yes 7% (1/15) 93% (14/15) 7% (1/15) 93% (14/15) 0% (0/15) 100% (15/15)
Surgical margin
Negative 39% (24/61) 61% (37/61) 0.176 38% (23/61) 62% (38/61) 0.075 25% (15/61) 75% (46/61) 0.232
Positive 26% (9/35) 74% (26/35) 20% (7/35) 80% (28/35) 14% (5/35) 86% (30/35)
PSA-defined recurrence
No 37% (33/89) 62% (54/87) 0.023 34% (30/87) 66% (57/87) 0.034 23% (20/87) 77% (67/87) 0.106
Yes 0% (0/7) 100% (9/9) 0% (0/9) 100% (9/9) 0% (0/9) 100% (9/9)
Abbreviations: CaP,¼prostate cancers; HEG¼high expression group; LEG¼low expression group; PSA¼prostate-specific antigen; RRP¼radical resection of the prostate.
aLEG
(Grade 0 or 1 immunostaining).
bHEG (X Grade 2 immunostaining).
c w
2-test; Po0.05 significant. The bold indicates the significant difference between groups in each parameter.
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smarkers (CD147, CD44v3-10), MDR-related protein (MDR1) and
monocarboxylate transporters (MCT1 and MCT4) was also found
in most metastatic CaP cell lines, as well as in primary CaP tissues.
To our knowledge, this is the first report investigating the
relationship between CD147, CD44v3-10, MDR1, MCT1 and
MCT4 during CaP progression.
The colocalisation of CD147 separately with several different
molecules, such as CD44v3-10, MDR1, MCT1 and MCT4, and the
colocalisation of CD44v3-10 with MDR1, MCT1 and MCT4 in
primary and metastatic CaP cells, suggests interactions between
these proteins. Toole and Slomiany (2008) reported that CD147
and CD44 interact with various multidrug transporters of the ABC
family and with MCTs associated with resistance to cancer
therapies. Slomiany et al (2009) reported that CD44 colocalises
with MCT1, MCT4 and CD147 at the plasma membrane, and HA,
CD44 and CD147 contributed to the regulation of MCT localisation
and function in the plasma membrane of breast cancer cells
(Slomiany et al, 2009). Colocalisation of CD44 and MDR1 was
shown to increase in melanoma cells engineered to express MDR,
compared with parental cells (Colone et al, 2008). Su et al (2009)
also found that CD147 colocalises with MCT1 and MCT4 in
membranes of malignant A375 melanoma cells, leading to an
increased glycolytic rate compared with that in normal human
melanocytes. Silencing of CD147 in A375 cells abrogates expres-
sion of MCT1 and MCT4, and colocalisation with CD147, and
dramatically decreases the cellular glycolytic rate, extracellular pH
and the production of ATP (Su et al, 2009). Our present data show
colocalisation of CD147 with MCT1 and MCT4 in primary and
metastatic CaP cells, consistent with CD147 being an ancillary
protein required for the expression of these MCTs (Deora et al,
2005; Gallagher et al, 2007). Our results support the hypothesis
that expression of CD147 is closely related to that of CD44v3-10,
and may be involved in regulating the expression of MDR1, MCT1
and MCT4 during CaP metastasis.
The expression of CD44 and its variants is associated with the
progression of several cancers, although this remains controversial
for CaP (De Marzo et al, 1998; Noordzij et al, 1999). One study
reported a complete lack of membranous expression of all CD44
isoforms in 93–98% primary CaP tissues (Kallakury et al, 1996),
whereas another reported moderate to high levels of CD44
expression in 60% of primary CaP, with B14% of metastases
expressing low levels of CD44 (Nagabhusha et al, 1996). Significant
reduction in CD44 expression was also reported in primary CaP
foci and metastases by De Marzo et al (1998). The relationship
between CD44 expression and tumour grade is also uncertain, with
a strong correlation between the Gleason grade of CaP and loss
of CD44 expression in one study (De Marzo et al, 1998), but no
correlation in another (Paradis et al, 1998). Similar to expression
studies, the potential role of CD44 in CaP development and
metastases is controversial. Earlier, overexpression experiments
have suggested that CD44 may exert a tumour-suppressive
function (Gao et al, 1998), although other studies have implicated
CD44 in CaP cell proliferation, adhesion, migration and invasion
CD147
CD147
CD147
CD147
CD44v3-10
CD44v3-10
CD44v3-10
CD147/CD44v3-10 CD44v3-10
CD147/MDR1 MDR1
CD147/MCT1 MCT1
CD147/MCT4 MCT4
CD44v3-10/MDR1 MDR1
CD44v3-10/MCT1 MCT1
CD44v3-10/MCT4 MCT4
Figure 5 Co-immunolabelling of CD147, CD44v3-10, MDR1, MCT1
and MCT4 in primary prostate cancer (CaP) tissues (different tumours
with a range of Gleason scores). Representative confocal images of CD147
and CD44v3-10 (green), CD44v3-10, MDR1, MCT1 and MCT4 (red)
immunolabelling are shown. Merged images and red and green
channels are shown separately. (A) CD147 and CD44v3-10 in high-grade
CaP (Gleason score¼8); (B) CD147 and MDR1 in high-grade CaP
(Gleason score¼8); (C) CD147 and MCT1 in low-grade CaP (Gleason
score¼6); (D) CD147 and MCT4 in high-grade CaP (Gleason score¼8);
(E) CD44v3-10 and MDR1 in high-grade CaP (Gleason score¼9);
(F) CD44v3-10 and MCT1 in high-grade CaP (Gleason score¼8); (G)
CD44v3-10 and MCT4 in high-grade CaP (Gleason score¼8). CD147
immunolabelling is seen on epithelial cell membranes and stromal cells.
CD44v3-10, MDR1, MCT1 and MCT4 immunostaining is predominantly
epithelial. MCT4 localises mostly to basal epithelial cells and to lateral cell
walls (magnification: A–G  400). The colour reproduction of the figure
is available on the html full text version of the paper.
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sin vitro, as well as in metastatic dissemination in vivo (Paradis
et al, 1998; Omara-Opyene et al, 2004). The variation in CD44
expression seen in different studies may be attributable to the use
of different methodologies in the assessment of CD44 expression
or to the different stages of CaPs used in the analyses or to the
use of different antibodies. Differences in the expressed CD44
isoform also explain some of these controversies. Non-invasive
prostate epithelial cells have been shown to express a high-
molecular-weight CD44 isoform, CD44v3-10, which may counter-
act the function of the standard isoform of CD44s by reducing
adhesion to and invasion of the endothelium by CaP cells
(Harrison et al, 2006).
In this study, we found CD44s expression in normal prostate
tissues and in a very low percentage of cells in CaP tissues (of
different stages, Hao J et al, unpublished data); CD44v3-10 was
negative in all normal prostate and PIN tissues. However, high
levels of expression of CD44v3-10 were correlated with tumour
grade, clinical stage, residual tumour and relapse, but not with
differences in tumour histological type. These observations
support the idea that in the development of CaP, CD44 isoform
expression changes progressively from CD44s to high-molecular-
weight variant forms such as CD44v3-10, and that CD44s basal cell
expression is lost with overexpression of variant forms in CaP cells
(Hao et al, 2010). The data suggest that CD44v3-10 is a marker of
progression of prostate epithelial cells from a benign to a
malignant phenotype, and thus may be an important indicator of
the stage of CaP, reflecting CaP progression and metastasis.
Aberrant MDR1 expression has been seen in many cancer types,
including CaP, and contributes significantly to treatment failure.
MDR1 expression was found to be associated with drug resistance
in androgen-dependent and androgen-independent human pros-
tate xenografts (Chen et al, 1998), whereas downregulation of
the MDR1 gene by hypermethylation has been associated with
an increase in cellular proliferation possibly related to disease
progression (Van Brussel et al, 2001; Enokida et al, 2004). In vitro
studies have also reported a functional interaction between
CD44 and MDR1, associated with increased cell migration,
in vitro invasion and metastasis (Miletti-Gonza ´lez et al., 2005).
Our analysis of primary CaP tumour samples of different stages/
grades before drug therapy has shown high levels of MDR1
expression to be correlated with tumour grade, clinical stage,
residual tumour and relapse, suggesting that MDR1 expression
may be involved in CaP progression and metastasis. We also found
that expression of CD147 and CD44v3-10 is colocalised in
metastatic CaP cells and inversely related to docetaxel sensitivity
in metastatic CaP cell lines, suggesting that CD147 and CD44v3-10
may be involved in CaP drug resistance. The functional roles of
CD147 and CD44v3-10 in CaP metastasis and drug resistance are
currently being investigated in our laboratory.
Increased glycolysis and adaptation to acidosis are key events
in the transition from in situ to invasive cancer (Gatenby and
Gillies, 2004). Given their essential function in exporting lactate,
the end product of glycolysis, MCTs are considered key elements
in regulating tumour intracellular pH and in the induction of
extracellular acidosis (Pinheiro et al., 2009). The rapid transport of
lactate through MCTs is of critical importance for tumour cells, by
which an increased glycolytic rate gives a proliferative advantage
over other cells. Upregulation of MCTs has been described in
several tumour types, but only three studies have evaluated its
clinicopathological significance (Pinheiro et al, 2008a,b, 2009). In
this paper, we demonstrate for the first time that the high level of
expression of MCT4 is correlated with CaP tumour grade, clinical
stage and residual tumour, as well as with relapse, but not with
differences in histological type, consistent with MCT1/MCT4
expression being involved in CaP progression.
We previously demonstrated CD147 expression in metastatic
CaP cell lines, primary CaP tissues and lymph node metastases
(Madigan et al, 2008). This has been ratified in this study, together
with overexpression of CD44v3-10, MDR1, MCT1, MCT4 and
colocalisation of CD147 and CD44v3-10, with MDR1, MCT1 and
MCT4 in CaP and stromal cells (data not shown) in most primary
tumours. The colocalisation of these markers in CaP tissues
is consistent with that seen in CaP cell lines, suggesting that cancer
clones that escape from primary tumours to the common
metastatic sites in human CaP do not lose expression of these
antigens. Differential expression of CD147, CD44v3-10, MDR1,
MCT1 and MCT4 also suggests that the phenotypes of CaP
metastasis may be controlled by genetics and/or by the tumour
microenvironment during CaP progression. Functional inter-
actions between CD44 and MDR1 are increasingly being recog-
nised as important in tumour metastases. For example, in breast
and ovarian cancer cell lines, immunoprecipitation and colocalisa-
tion studies, together with functional assays, showed that CD44
and MDR can directly influence the expression of each other,
producing a malignant tumour cell phenotype characterised by
MDR, increased migration and invasion (Miletti-Gonza ´lez et al.,
2005). The colocalisation of CD147 with CD44v3-10, MDR1,
MCT1 and MCT4 in this study further suggests that CD147
and CD44v3-10 could concomitantly regulate MDR1, MCT1 and
MCT4 expression during CaP progression, associated with drug
resistance. However, the mechanisms involved in CD147 and
CD44v3-10 regulation during CaP metastasis require further study.
Given that CD147 and CD44v3-10 colocalise with MDR1-positive
cells in CaP specimens, their targeting could potentially overcome
drug resistance in the late stage of metastatic CaP.
Previous studies have shown that CD147 knockdown using
siRNA (Wang et al, 2006) or antibodies (Xu et al, 2007; Dean et al,
2009) inhibits tumour growth in vitro or in vivo, associated with
changes in the regulation of MMP production (Xu et al, 2007,
Dean et al, 2009) and radiation sensitivity of the tumours
(Dean et al, 2009). Schneiderhan et al (2009) further confirmed
that CD147 silencing inhibits lactate transport and reduces
malignant potential of pancreatic cancer cells in in vitro and
in vivo models. MCT1 inhibition has also been shown to have
anti-tumour potential against in vivo models of lung carcinoma,
colorectal carcinoma and a squamous carcinoma cell line after
a-cyano-4-hydroxycinnamate-mediated MCT1 inhibition (Sonveaux
et al, 2008). These results suggest that targeting CD147 could be
useful in controlling metastasis and cancer recurrence, with potential
application to CaP.
Targeting overexpressed CD44 in cancer cells may also control
CaP progression. Antibody-mediated CD44 targeting has inhibited
growth of breast cancer xenografts and prevented regrowth of
basal-like HBCx cells after chemotherapy-induced remission
(Marangoni et al, 2009). Gene therapy using siRNA CD44 also
caused in vitro and in vivo regression of HT colon cancer cells
(Subramaniam et al, 2007). Several reviews have also discussed the
advantages of HA (major CD44 ligand) as a drug carrier and a
targeting ligand for cancer, as well as other pathologies (Platt and
Szoka, 2008; Yadav et al, 2008). It has also been used with prodrugs
against cancer cell lines and xenografts (Auzenne et al, 2007) or in
novel lipoplexes to target siRNA (Taetz et al, 2009), or for gene
delivery (Surace et al, 2009). The potential for these approaches in
CaP, alone or in combination with CD147-targeted therapies
(discussed above), is promising and remains to be investigated in
future studies.
In summary, we have demonstrated co-expression of CD147 and
CD44v3-10 with MDR1, MCT1 and MCT4 in most CaP metastatic
cell lines and in primary CaP tissues. The overexpression of
CD44v3-10, MDR1 and MCT4 was significantly associated with
CaP progression. Colocalisation of CD147 and CD44v3-10 with
MDR1 and MCTs in tumour and stromal cells suggests a role
for these invasive markers in the regulation of drug resistance in
the progression of CaP, consistent with our in vitro docetaxel
sensitivity findings. Our results further indicate that both CD147
and CD44v3-10 may be potential therapeutic targets for treating
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slate-stage, incurable, recurrent metastatic CaP to overcome drug
resistance.
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